On 5 July 2019, global healthcare company GSK opened a new $130 million pharmaceutical manufacturing facility in Jurong that was developed as part of the GSK-Economic Development Board 10-year Singapore Manufacturing Roadmap. The investment demonstrates GSK's commitment to Singapore as a key manufacturing and supply site for GSK's global pharmaceutical business and a testbed for advanced manufacturing technology.
GSK also expanded one of the production buildings on its Jurong site. These developments will enable the site, a leading facility within GSK’s pharmaceutical supply chain, to accelerate the supply of new breakthrough medicines to patients globally.
Speaking at the launch ceremony, Minister of Trade and Industry of Singapore Mr Chan Chun Sing affirmed that the cooperation between the Singaporean government, companies and workers is what enables Singapore to maintain its position as the global biomedical centre producing high quality pharmaceutical products. Mr Chan also stressed the importance of the fundamentals that has helped Singapore to be at the forefront of the industry – developing trusted partnerships with industry players, how Singapore protects intellectual property and how workers are trained.
Mr Chng Kai Fong, Managing Director, Singapore Economic Development Board said, “Over the years, GSK has continually partnered with Singapore to develop advanced manufacturing technologies, such as continuous manufacturing and digital manufacturing. They have also been a strong partner in training our local talent. These efforts have supported the growth of the industry as a whole and in turn has created diverse and attractive job opportunities for Singapore.”
Mr M. Selvaraju, a 56-year-old production leader at GSK, was sent overseas for training and has helped to coach others to learn new processes in continuous manufacturing.
